IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 36 filers reported holding IMPEL NEUROPHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,755 | -80.1% | 178,500 | -41.2% | 0.04% | -79.4% |
| Q2 2023 | $385,578 | -28.1% | 303,605 | -20.8% | 0.20% | -37.8% |
| Q1 2023 | $536,410 | -56.1% | 383,148 | +17.6% | 0.33% | -60.3% |
| Q4 2022 | $1,221,844 | -46.5% | 325,825 | -30.6% | 0.83% | -44.0% |
| Q3 2022 | $2,285,000 | -44.1% | 469,183 | +7.0% | 1.48% | -39.4% |
| Q2 2022 | $4,087,000 | +74.8% | 438,566 | +19.5% | 2.43% | +137.7% |
| Q1 2022 | $2,338,000 | +5.8% | 367,058 | +43.4% | 1.02% | +14.3% |
| Q4 2021 | $2,210,000 | +21.0% | 256,027 | +70.7% | 0.90% | +11.2% |
| Q3 2021 | $1,827,000 | – | 150,000 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LASRY MARC | 408,329 | $1,989,000 | 3.82% |
| venBio Partners LLC | 2,759,791 | $13,440,000 | 3.11% |
| 5AM Venture Management, LLC | 2,884,791 | $14,049,000 | 2.69% |
| Vivo Capital, LLC | 2,884,789 | $14,049,000 | 1.55% |
| DCF Advisers, LLC | 469,183 | $2,285,000 | 1.48% |
| Opaleye Management Inc. | 255,250 | $1,243,000 | 0.51% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $20,142,000 | 0.40% |
| EPIQ PARTNERS, LLC | 18,646 | $91,000 | 0.06% |
| GILDER GAGNON HOWE & CO LLC | 142,696 | $695,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 68,300 | $333,000 | 0.01% |